{"product_id":"generic-crizotinib","title":"Kayzoni (Crizotinib)","description":"\u003cp\u003eCrizotinib is a prescription medicine used to treat people with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by a defect in either a gene called ALK (anaplastic lymphoma kinase) or a gene called ROS1.\u003c\/p\u003e\u003ch3\u003eNon-Small Cell Lung Cancer\u003c\/h3\u003e\u003cp\u003eIndicated for metastatic non-small cell lung cancer (NSCLC) in adults whose tumors are anaplastic lymphoma kinase (ALK)- or ROS1-positive\u003c\/p\u003e\u003cp\u003e250 mg PO BID\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003eInflammatory Myofibroblastic tumors\u003c\/h3\u003e\u003cp\u003eIndicated for unresectable, recurrent, or refractory inflammatory myofibroblastic tumors (IMT) in adults who are ALK-positive\u003c\/p\u003e\u003cp\u003e250 mg PO BID\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eFirst dose reduction: 200 mg PO BID\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 250 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eUnable to tolerate 250 mg PO qDay: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797948756011,"sku":"RL1020230315560","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-04-1046.jpg?v=1787022123","url":"https:\/\/xomeds.com\/products\/generic-crizotinib","provider":"XOMEDS","version":"1.0","type":"link"}